DDR2, on the other hand, has been linked to higher tumor grade and shorter survival in breast cancer, as well as metastasis in gastric cancer, advanced staging in head and neck cancers, and increased risk of metastasis in ovarian cancer (Table 1) [85,111,112,113]. Here, DDR2 is linked to ovarian carcinoma.